Shots:
- The UK’s MHRA has approved Oczyesa (octreotide SC depot) for the maintenance treatment in adult with acromegaly who have responded to & tolerated somatostatin analogs, following EC approval on Jun 30, 2025; UK launch expected in Q4’25
- Approval was based on extensive data from 7 trials, incl. 4 P-I trials, 1 P-II trials & 2 P-III (ACROINNOVA 1 & 2) trials, where ACROINNOVA 1 showed superior IGF-1 normalization vs PBO, with ACROINNOVA 2 validating the results over 52wks., incl. sustained symptom relief, improved QoL, & higher treatment satisfaction
- Additionally, Oczyesa is being evaluated in P-III (SORENTO) trial for gastroenteropancreatic neuroendocrine tumors & P-II/III (POSITANO) trial for polycystic liver disease
Ref: Camurus | Image: Camurus| Press Release
Related News:- Camurus Reports Topline P-IIb (POSITANO) Trial Data on CAM2029 for Symptomatic Polycystic Liver Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
